Stockscreener 앱 받기
107.08
1.14%
1.21
Gilead Sciences Inc 주식(GILD)의 최신 뉴스
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences Inc (GILD) - GuruFocus.com
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed - Benzinga
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
GILD Stock Down on Report of Cut in HIV Prevention Spending - TradingView
Oppenheimer doesn’t see threat to Gilead estimates after HHS plans for HIV cuts - Yahoo Finance
Gilead Stock Wobbles On Federal HIV Funding Cut Buzz, But Retail And Analysts Stay Unfazed - MSN
Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides - Yahoo Finance
Gilead Stock Falls on Report U.S. Could Slash HIV-Prevention Budget - The Wall Street Journal
Gilead stock falls on report of HIV prevention cuts - Yahoo Finance
Gilead Stock Dives On A Devastating Potential Call From HHS - Investor's Business Daily
Stock of the Day: Gilead Sciences falls on report the Trump administration could slash funds for HIV prevention - Yahoo Finance
Wall Street weighs in on Gilead as shares fall on possible U.S. HIV cuts - Investing.com Canada
BMO reiterates Gilead stock with $115 target amid HIV funding concerns - Investing.com
Citi maintains Gilead stock Buy rating, $125 target amid HIV funding fears - Investing.com
Gilead Sciences Should Not See Any Impact From HIV-Related Cost Reductions at US Healthcare Department, Truist Says - Marketscreener.com
Gilead Sciences Ranked in Top Five Most JUST List for Biopharma Companies - CSRwire.com
Gilead Sciences’ SWOT analysis: HIV giant’s stock faces pivotal transition - Investing.com
Gilead Sciences Stock Slips on Possible HIV Funding Cut - Schaeffers Research
Why Gilead Sciences (GILD) Is Among the Most Undervalued Biotech Stocks to Invest In - Insider Monkey
Citi Defending Gilead Sciences (GILD): 'we are buyers of GILD stock on any weakness ahead of the upcoming Len PrEP launch in mid-2025' - StreetInsider.com
Gilead Stock Falls on Report Trump Administration Wants to Cut HIV-Prevention Funding - Barron's
Gilead Stock (NYSE:GILD) Slumps on HIV Funding Cuts Report - TipRanks
Gilead slides as Trump administration puts HIV prevention funds under review - TradingView
Gilead Sciences (GILD): Potential Impact of Federal HIV Funding Cuts - Value the Markets
Gilead, GSK could be impacted by potential HHS HIV prevention cuts - Seeking Alpha
Gilead Sciences CFO Andrew Dickinson sells $276,325 in stock - Investing.com
After-hours movers: Gilead Sciences, HealthEquity, CARGO Therapeutics and more - Investing.com
Gilead Sciences stock falls on potential HIV funding cuts By Investing.com - Investing.com Australia
Gilead Sciences stock falls on potential HIV funding cuts - Investing.com
Unpacking the Latest Options Trading Trends in Gilead Sciences - Benzinga
Gilead Sciences (GILD): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
Coronavirus: La Commission européenne signe un accord avec Gilead sur le remdesivir - Reuters
Is Gilead Sciences, Inc. (GILD) a Best Biotech Stock According to Billionaires? - Yahoo Finance UK
7 Most Undervalued Biotech Stocks To Invest In - Insider Monkey
GILD Stock Trading Close to Its 52-Week High: Should You Buy or Sell? - Yahoo Finance
Gilead SciencesWomen's History Month Celebrated With Its Team - CSRwire.com
Is Gilead Sciences, Inc. (GILD) The Most Undervalued NASDAQ Stock To Buy According To Hedge Funds? - Insider Monkey
Gilead: Growth Constraints Lead To Rating Downgrade Following 50% Rally - Seeking Alpha
Gilead's accounting chief hits the exit—Chutes & Ladders - Fierce Biotech
Gilead Sciences: A rare Nasdaq gem with consistent returns across time horizons - The Financial Express
Merck’s HIV Combo Shows Non-Inferiority To Gilead’s Biktarvy - Citeline News & Insights
Is Gilead Sciences Gaining or Losing Market Support? - Benzinga
1.54%
0.34%
자본화:
|
볼륨(24시간):